When targeting problem proteins involved in causing or spreading disease, a drug will often clog up a protein’s active site so it can’t function and wreak havoc.
A once-public psychedelic biotech reemerges with $103M from MPM and Novo Holdings
MPM BioImpact and Novo Holdings are among a group of investors pouring $103 million into a psychedelic biotech that MPM took private last summer. Reunion